[go: up one dir, main page]

KR960705843A - 펩티딜 화합물과 메탈로프로테인아제의 억제제로서 그들의 치료학적 용도(peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases) - Google Patents

펩티딜 화합물과 메탈로프로테인아제의 억제제로서 그들의 치료학적 용도(peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases)

Info

Publication number
KR960705843A
KR960705843A KR1019960702437A KR19960702437A KR960705843A KR 960705843 A KR960705843 A KR 960705843A KR 1019960702437 A KR1019960702437 A KR 1019960702437A KR 19960702437 A KR19960702437 A KR 19960702437A KR 960705843 A KR960705843 A KR 960705843A
Authority
KR
South Korea
Prior art keywords
alkyl
methylamide
aryl
phenylalanine
leusil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1019960702437A
Other languages
English (en)
Inventor
존 몬타나
존나단 디킨즈
데이비드 알렌 오웬
앤드류 더글러스 박스터
Original Assignee
앤드류 리차드
키로사이언스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앤드류 리차드, 키로사이언스 리미티드 filed Critical 앤드류 리차드
Publication of KR960705843A publication Critical patent/KR960705843A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 하기의 식(Ⅰ)의 화합물로서,
여기서 R1은 C1-6알킬, C2-6알케닐, 아릴, (C1-6알킬)아릴 또는 C1-6알킬-AR9이고, A는 O, NR9이고, 또는 S(O)m이고, m은 0 내지 2이고, R9은 H, C1-4알킬, 아릴 또는 (C1-4알킬)아릴; R2는 H 또는 C1-6알킬; R4는 H 또는 아미노(NH2), 아릴 아미노, 보호된 아미노, 아릴, 디(C1-6알킬)아미노, 모노(C1-6알킬)아미노, CO2H, 보호된 카르복실, 카르바모일, 모노(C1-6알킬)카르바모일 또는 디(C1-6알킬)카르바모일에 의해 선택적으로 치환된 C1-6알킬, 및 R5는 H 또는 C1-6알킬, 또는 NR4R5은 피롤리디노, 피페리디도 또는 모르포리노; R6는 선택적으로 치환된 C3-6시클로알킬, C3-6시클로알케닐, C1-6알킬, 벤질, (C1-6알콕시)벤질, 벤질옥시벤질 또는 3-인돌리메틸; Alk는 C1-6알킬 또는 C2-6알케닐 및 n=0 또는 1; R7은 H 또는 R10CO, 여기서 R10은 C1-4알킬, (C1-4알킬)아릴, C3-6시클로알킬, (C3-6시클로알킬) C1-4알킬, C2-6알케닐 또는 (C2-6알케닐)아릴; 및 R8은 H, C1-4알킬, (C1-4알킬)아릴 또는 아릴; 또는 그들의 염, 솔베이트 또는 수화물이다.
이런 화합물들은 메타로프로테인아제, TNF 및/또는 다른 활성도와 관련된 상태를 처리하는데 사용될 수 있다.

Description

펩티딜 화합물과 메탈로프로테인아제의 억제제로서 그들의 치료학적 용도(PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEINASES)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 하기 일반식(Ⅰ)의 화합물, 또는 그들의 염, 솔베이트 또는 수화물.
    여기서 R1은 C1-6알킬, C2-6알케닐, 아릴, (C1-6알킬)아릴 또는 C1-6알킬-AR9이고, A는 O, NR9이고, 또는 S(O)m이고, m은 0 내지 2이고, R9은 H, C1-4알킬, 아릴 또는 (C1-4알킬)아릴; R2는 H 또는 C1-6알킬; R4는 H 또는 아미노(NH2), 아릴 아미노, 보호된 아미노, 아릴, 디(C1-6알킬)아미노, 모노(C1-6알킬)아미노, CO2H, 보호된 카르복실, 카르바모일, 모노(C1-6알킬)카르바모일 또는 디(C1-6알킬)카르바모일에 의해 선택적으로 치환된 C1-6알킬, 및 R5는 H 또는 C1-6알킬, 또는 NR4R5은 피롤리디노, 피페리디노 또는 모르포리노; R6는 선택적으로 치환된 C3-6시클로알킬, C3-6시클로알케닐, C1-6알킬, 벤질, (C1-6알콕시)벤질, 벤질옥시벤질 또는 3-인돌리메틸, Alk는 C1-6알킬 또는 C2-6알케닐 및 n=0 또는 1; R7은 H 또는 R10CO, 여기서 R10은 C1-4알킬, (C1-4알킬)아릴, C3-6시클로알킬, (C3-6시클로알킬)C1-4알킬, C2-6알케닐 또는 (C2-6알케닐)아릴; 및 R8은 H, C1-4알킬, (C1-4알킬)아릴 또는 아릴이다; 또는 그들의 염, 솔베이트 또는 수화물.
  2. 제1항에 있어서, R1은 알킬, 알케닐, 아릴, 알킬아릴이고, R7및 R8은 각각 H인 화합물.
  3. 제1항에 있어서, 화합물은 N-〔N-(메르캅토아세틸)-L-레우실〕-L-페닐알라닌 메틸아미드, N-〔(아세토메르캅토아실)-L-레우실〕-L-페닐알라닌 메틸아미드, (RS)
    -2-(아세틸티오)펜타노일-L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-(아세틸티오)프로파노일-L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-(아세틸티오)-3-메틸부타노일-L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-(아세틸티오)-2-페닐아세틸
    -L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-(아세틸티오)-3-페닐프로파노일-L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-(아세틸티오)-4-페닐부타노일-L-레우실
    -L-페닐알라닌 N-메틸아미드, N-(아세틸메르캅토아실)-L-트레오닐-L-페닐알라닌 메틸아미드, N-(아세틸메르캅토아실)-L-트레오닐-L-레우실-L-트립토판 메틸아미드, (RS)-2-메르캅토펜타노일-L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-메르캅토프로파노일-L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-메르캅토-3-메틸부타노일-L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-메르캅토-2-페닐아세틸-L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-메르캅토-3-페닐프로파노일-L-레우실-L-페닐알라닌 N-메틸아미드, N-〔N-(메르캅토아세틸)-L-트레오닐〕-L-페닐알라닌 메틸아미드 및 N-〔N-(메르캅토아세틸)-L-레우실〕-L-트립토판 메틸아미드로부터 선택된 화합물.
  4. 제1항 내지 제3항 중 어느 하나의 항의 화합물과 생리학적으로 허용가능한 희석액 또는 담체로 이루어지는 치료에 사용하기 위한 제약학적 조성물.
  5. 매트릭스 메탈로프로테인아제 또는 TNF 활성과 관련된 상태의 억제 또는 치료를 위한 약제의 제조를 위한 제1항 내지 제3항 중 어느 하나의 항의 화합물의 용도.
  6. 제5항에 있어서, 상기 상태는 염증, 발열, 심장맥관의 효과, 출혈, 응고 및 급성상태 반응, 악태증 및 식욕결핍, 급성 간염, 쇼크 상태, 조직이식 대 숙주 반응, 자가면역 질병, 말라리아, 리퍼퓨션(reperfusion)질병, 수막염, 건선, 류마토이드 관절염, 다중 경화증 및 종양들로부터 선택되는 화합물의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960702437A 1993-11-10 1994-11-10 펩티딜 화합물과 메탈로프로테인아제의 억제제로서 그들의 치료학적 용도(peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases) Abandoned KR960705843A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9323165.2 1993-11-10
GB939323165A GB9323165D0 (en) 1993-11-10 1993-11-10 Compounds
PCT/GB1994/002471 WO1995013289A1 (en) 1993-11-10 1994-11-10 Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases

Publications (1)

Publication Number Publication Date
KR960705843A true KR960705843A (ko) 1996-11-08

Family

ID=10744943

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960702437A Abandoned KR960705843A (ko) 1993-11-10 1994-11-10 펩티딜 화합물과 메탈로프로테인아제의 억제제로서 그들의 치료학적 용도(peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases)

Country Status (21)

Country Link
US (1) US5853623A (ko)
EP (1) EP0728144B1 (ko)
JP (1) JPH09505041A (ko)
KR (1) KR960705843A (ko)
CN (1) CN1134705A (ko)
AT (1) ATE188969T1 (ko)
AU (1) AU679286B2 (ko)
BR (1) BR9408025A (ko)
CA (1) CA2173470A1 (ko)
CZ (1) CZ287780B6 (ko)
DE (1) DE69422726T2 (ko)
DK (1) DK0728144T3 (ko)
ES (1) ES2143611T3 (ko)
FI (1) FI961976A0 (ko)
GB (1) GB9323165D0 (ko)
GR (1) GR3033103T3 (ko)
HU (1) HU217344B1 (ko)
NO (1) NO961888D0 (ko)
PL (1) PL180403B1 (ko)
PT (1) PT728144E (ko)
WO (1) WO1995013289A1 (ko)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU687436B2 (en) * 1993-08-23 1998-02-26 Immunex Corporation Inhibitors of TNF-alpha secretion
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
CN1193978A (zh) 1994-10-05 1998-09-23 奇罗斯恩有限公司 肽基化合物和它们作为金属蛋白酶抑制剂的医疗用途
DE69624477T2 (de) * 1995-05-10 2003-06-26 Darwin Discovery Ltd., Cambridge Peptide, die metallproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung
US5981491A (en) * 1995-05-10 1999-11-09 Darwin Discovery Limited Peptidyl compounds and their therapeutic use
JPH11504934A (ja) * 1995-05-10 1999-05-11 カイロサイエンス・リミテッド 金属プロテアーゼとｔｎｆの放出を抑制するペプチジル化合物およびその治療的使用
US5677282A (en) * 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
GB9514867D0 (en) * 1995-07-20 1995-09-20 British Biotech Pharm Metalloproteinase inhibitors
GB2318353B (en) * 1995-07-20 1999-10-06 British Biotech Pharm Metalloproteinase inhibitors
JP2008024720A (ja) * 1995-07-26 2008-02-07 Mitsubishi Chemicals Corp ペニシラミンアミド誘導体
CN1145637C (zh) * 1995-10-05 2004-04-14 达尔文发现有限公司 作为金属蛋白酶和tnf释放抑制剂的硫取代的肽
AU7139996A (en) * 1995-10-05 1997-04-28 Chiroscience Limited Mercaptoamide derivatives and their therapeutic use
GB9523066D0 (en) * 1995-11-10 1996-01-10 Chiroscience Ltd Compounds and their therapeutic use
CZ291337B6 (cs) * 1995-11-22 2003-02-12 Darwin Discovery Limited Merkaptoalkylpeptidylová sloučenina, její použití pro výrobu přípravku pro léčení nebo prevenci stavu souvisejícího s metalloproteinázou nebo TNFalfa a farmaceutický přípravek ji obsahující
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
KR100338861B1 (ko) 1996-01-23 2003-02-20 시오노기세이야쿠가부시키가이샤 술폰화아미노산유도체및이를함유한메탈로프로테이나제저해제
GB9607119D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607249D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US6069150A (en) * 1996-04-04 2000-05-30 F. Hoffman-La Roche Ag Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9609702D0 (en) 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
US5852213A (en) * 1996-07-10 1998-12-22 American Cyanamid Company Mercaptoketones and mercaptoalcohols and a process for their preparation
US6013649A (en) * 1996-07-22 2000-01-11 Monsanto Company Thiol sulfone metalloprotease inhibitors
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
GB9624817D0 (en) * 1996-11-28 1997-01-15 British Biotech Pharm Metalloproteinase inhibitors
AU741903C (en) * 1997-03-03 2002-09-05 Darwin Discovery Limited Selective MMP inhibitors having reduced side-effects
US6638952B1 (en) 1997-03-04 2003-10-28 Pharmacia Corporation Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
AU750130B2 (en) 1997-03-04 2002-07-11 Monsanto Company Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
WO1999007679A1 (en) * 1997-08-08 1999-02-18 Chiroscience Limited Peptidyl compounds having mmp and tnf inhibitory activity
AU756150C (en) 1997-11-14 2004-03-04 G.D. Searle & Co. Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
AUPP508798A0 (en) * 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
ATE249429T1 (de) * 1998-12-31 2003-09-15 Aventis Pharma Inc Amidomalonimide und ihre anwendung als matrix metalloproteinase-inhibitoren
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
GEP20043238B (en) 1999-02-08 2004-05-25 Searle & Co Sulfamato Hydroxamic Acid Metalloprotease Inhibitor, its Use in Preparation of Pharmaceutical Composition for Treatment of Conditions Associated with Pathological Matrix Metalloprotease Activity
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
JP2003521476A (ja) * 1999-06-15 2003-07-15 メルク エンド カムパニー インコーポレーテッド チオール誘導体、メタロ−β−ラクタマーゼ阻害剤
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
US6696456B1 (en) * 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
CA2403778A1 (en) * 2000-03-21 2001-09-27 The Procter & Gamble Company Carbocyclic side chain containing metalloprotease inhibitors
WO2001070693A2 (en) * 2000-03-21 2001-09-27 The Procter & Gamble Company Difluorobutyric acid derivatives and their use as metalloprotease inhibitors
BR0109328A (pt) * 2000-03-21 2003-06-10 Procter & Gamble Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
FR2823212B1 (fr) * 2001-04-10 2005-12-02 Inst Nat Sante Rech Med Inhibiteurs de la toxine botulique de type b
BR0209525A (pt) 2001-05-11 2004-03-09 Pharmacia Corp Hidroxamatos de sulfona aromáticos e uso dos mesmos como inibidores de protease
EP1501827A2 (en) 2002-04-25 2005-02-02 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acid and their use as protease inhibitors
ATE465757T1 (de) * 2002-08-20 2010-05-15 Astellas Pharma Inc Hemmer des abbaus der extrazellulären matrix von arthrodia-knorpel
DE60331367D1 (de) 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US7570250B2 (en) * 2006-05-04 2009-08-04 Yi-Ming Tseng Control device including a ball that stores data
JP2012523438A (ja) 2009-04-10 2012-10-04 タフツ メディカル センター インコーポレイテッド メタロプロテイナーゼ−１（ｍｍｐ−１）によるｐａｒ−１活性化
HRP20220479T1 (hr) 2016-06-01 2022-05-27 Athira Pharma, Inc. Spojevi

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ223037A (en) * 1986-12-24 1991-04-26 Beecham Group Plc Thiol-carboxylic acid derivatives and pharmaceutical compositions thereof
WO1988006890A1 (en) * 1987-03-17 1988-09-22 Research Corporation Technologies, Inc. Synthetic inhibitors of mammalian collagenase
US5144043A (en) * 1988-06-15 1992-09-01 Centocor Cleavable bifunctional coupling agents
WO1994007481A1 (en) * 1992-10-02 1994-04-14 Merck & Co., Inc. N-(mercaptoacyl)peptidyl derivatives as antidegenerative agents

Also Published As

Publication number Publication date
AU679286B2 (en) 1997-06-26
HU217344B1 (hu) 2002-02-28
JPH09505041A (ja) 1997-05-20
EP0728144A1 (en) 1996-08-28
CN1134705A (zh) 1996-10-30
HK1015139A1 (en) 1999-10-08
GR3033103T3 (en) 2000-08-31
DK0728144T3 (da) 2000-07-03
PT728144E (pt) 2000-07-31
US5853623A (en) 1998-12-29
HUT73799A (en) 1996-09-30
DE69422726T2 (de) 2000-06-08
CZ287780B6 (en) 2001-02-14
PL180403B1 (pl) 2001-01-31
ES2143611T3 (es) 2000-05-16
HU9601244D0 (en) 1996-07-29
NO961888L (no) 1996-05-09
PL314300A1 (en) 1996-09-02
WO1995013289A1 (en) 1995-05-18
FI961976A7 (fi) 1996-05-09
CZ134996A3 (en) 1996-10-16
BR9408025A (pt) 1996-12-17
EP0728144B1 (en) 2000-01-19
FI961976A0 (fi) 1996-05-09
AU8113394A (en) 1995-05-29
ATE188969T1 (de) 2000-02-15
NO961888D0 (no) 1996-05-09
DE69422726D1 (de) 2000-02-24
CA2173470A1 (en) 1995-05-18
GB9323165D0 (en) 1994-01-05

Similar Documents

Publication Publication Date Title
KR960705843A (ko) 펩티딜 화합물과 메탈로프로테인아제의 억제제로서 그들의 치료학적 용도(peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases)
WO1995013289B1 (en) Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
UA39093C2 (uk) Похідні пептидів, що є інгібіторами еластази лейкоцитів людини, спосіб їх отримання та фармацевтична композиція
RU95108387A (ru) Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина
KR910016765A (ko) 아세트산 유도체
RU94022258A (ru) Новые сульфониламинопиримидины
YU22402A (sh) Nova klasa agenasa za citodiferencijaciju i inhibitora histon deacetilaze, i postupci za njihovu upotrebu
DK0827743T3 (da) Anvendelse af histondecarboxylase-hæmmere til behandling af fibrose
CA2300051A1 (en) Amide derivatives for the treatment of diseases mediated by cytokines
KR930009993A (ko) 혈전증 치료제
DK0874808T3 (da) Biphenyl-hydroxamat-inhibitorer for matrix-metalloproteinaser
ATE353319T1 (de) Acetylenderivate als inhibitoren von histondeacetylase
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
ATE209177T1 (de) Von einem aromatischen oder heteroaromatischen radikal substituierte biphenylderivate und diese enthaltende pharmaceutische und kosmetische compositionen
RU94044456A (ru) Средство для подавления дисфункционального маточного кровотечения
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
NZ333550A (en) Matrix metalloproteinase inhibitors for inhibiting the release of TNF
RU94045280A (ru) Средство для ингибирования патологических состояний молочных желез
BR9910678A (pt) Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto
DE69315699D1 (de) Inhibitoren gegen die aggregation von blutplättchen
NO308607B1 (no) Kjemisk forbindelse, et farmasøytisk preparat inneholdende denne, samt anvendelse av forbindelsen til fremstilling av en blodplateaggregeringsinhibiotor og fremstilling av et farmasøytisk preparat til behandling eller forebygging av trombotiske
UY24425A1 (es) Derivados de tiol con actividad inhibidora de metalopeptidasa.
UA35623C2 (uk) Похідні аміду фенілциклогексилкарбонової кислоти, суміш їх ізомерів чи окремі ізомери і їх солі, фармацевтична композиція з антиартеріосклеротичною і антирестенозною активністю
BR9916505A (pt) O emprego de inibidores da troca desódio-hidrogênio para a preparação de ummedicamento para evitar disfunções de órgãoscondicionadas pela idade, doenças condicionadaspela idade e para o prolongamento da vida
TW339335B (en) Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19960509

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19990929

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20010828

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20020625

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20010828

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20020723

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20020625

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20020923

Appeal identifier: 2002101002841

Request date: 20020723

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20020723

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20020723

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20020128

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20020923

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20020902

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee